DK1173222T3 - Konjugat med en spaltelig binding til brug i et liposom - Google Patents
Konjugat med en spaltelig binding til brug i et liposomInfo
- Publication number
- DK1173222T3 DK1173222T3 DK00928321T DK00928321T DK1173222T3 DK 1173222 T3 DK1173222 T3 DK 1173222T3 DK 00928321 T DK00928321 T DK 00928321T DK 00928321 T DK00928321 T DK 00928321T DK 1173222 T3 DK1173222 T3 DK 1173222T3
- Authority
- DK
- Denmark
- Prior art keywords
- liposome
- conjugate
- cleavable bond
- amine
- hydrophilic polymer
- Prior art date
Links
- 239000002502 liposome Substances 0.000 title 1
- 150000001412 amines Chemical class 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000004396 dithiobenzyl group Chemical group 0.000 abstract 1
- 229920001477 hydrophilic polymer Polymers 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
- A61K47/544—Phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/10—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C323/18—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
- C07C323/19—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton with singly-bound oxygen atoms bound to acyclic carbon atoms of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
- C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/553—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with halogen atoms or nitro radicals directly attached to ring carbon atoms, e.g. fluorouracil
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
- C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
- C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/12—Triazine radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
- Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
- Y10T428/2984—Microcapsule with fluid core [includes liposome]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Dispersion Chemistry (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Botany (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Dental Preparations (AREA)
- Manufacturing Of Micro-Capsules (AREA)
- Cosmetics (AREA)
- Compositions Of Macromolecular Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Detergent Compositions (AREA)
- Solid-Sorbent Or Filter-Aiding Compositions (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13089799P | 1999-04-23 | 1999-04-23 | |
PCT/US2000/010922 WO2000064484A2 (en) | 1999-04-23 | 2000-04-21 | Conjugate having a cleavable linkage for use in a liposome |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1173222T3 true DK1173222T3 (da) | 2007-01-29 |
Family
ID=22446872
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK00928321T DK1173222T3 (da) | 1999-04-23 | 2000-04-21 | Konjugat med en spaltelig binding til brug i et liposom |
Country Status (18)
Country | Link |
---|---|
US (8) | US6365179B1 (da) |
EP (3) | EP1579874A3 (da) |
JP (1) | JP4558952B2 (da) |
KR (2) | KR100669053B1 (da) |
CN (2) | CN100512879C (da) |
AT (1) | ATE340592T1 (da) |
AU (1) | AU769425B2 (da) |
CA (1) | CA2369595C (da) |
DE (1) | DE60030965T2 (da) |
DK (1) | DK1173222T3 (da) |
ES (1) | ES2272280T3 (da) |
HK (1) | HK1041820B (da) |
HU (2) | HUP0200797A3 (da) |
IL (2) | IL146055A0 (da) |
MX (2) | MXPA01010750A (da) |
NO (1) | NO20015144L (da) |
WO (1) | WO2000064484A2 (da) |
ZA (2) | ZA200108724B (da) |
Families Citing this family (94)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5981501A (en) * | 1995-06-07 | 1999-11-09 | Inex Pharmaceuticals Corp. | Methods for encapsulating plasmids in lipid bilayers |
US7422902B1 (en) * | 1995-06-07 | 2008-09-09 | The University Of British Columbia | Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer |
CA2289702C (en) | 1997-05-14 | 2008-02-19 | Inex Pharmaceuticals Corp. | High efficiency encapsulation of charged therapeutic agents in lipid vesicles |
US7238368B2 (en) * | 1999-04-23 | 2007-07-03 | Alza Corporation | Releasable linkage and compositions containing same |
KR100669053B1 (ko) * | 1999-04-23 | 2007-01-15 | 알자 코포레이션 | 리포좀에 사용하기 위한 절단가능 결합을 갖는 콘쥬게이트 |
US7112337B2 (en) * | 1999-04-23 | 2006-09-26 | Alza Corporation | Liposome composition for delivery of nucleic acid |
US7303760B2 (en) | 1999-04-23 | 2007-12-04 | Alza Corporation | Method for treating multi-drug resistant tumors |
GB9915074D0 (en) * | 1999-06-28 | 1999-08-25 | Cortecs Plc | Ligand-binding composition |
US7094423B1 (en) * | 1999-07-15 | 2006-08-22 | Inex Pharmaceuticals Corp. | Methods for preparation of lipid-encapsulated therapeutic agents |
US7108863B2 (en) | 2001-03-26 | 2006-09-19 | Alza Corporation | Liposome composition for improved intracellular delivery of a therapeutic agent |
EP1389209B1 (en) * | 2001-04-24 | 2009-04-08 | Purdue Research Foundation | Folate mimetics and folate-receptor binding conjugates thereof |
WO2003039595A2 (en) * | 2001-11-07 | 2003-05-15 | Inex Pharmaceuticals Corporation | Mucosal adjuvants comprising an oligonucleotide and a cationic lipid |
US7842498B2 (en) * | 2001-11-08 | 2010-11-30 | Bio-Rad Laboratories, Inc. | Hydrophobic surface chip |
US7211440B2 (en) | 2002-03-08 | 2007-05-01 | Wallac Oy | Dissociative fluorescence enhancement assay |
US6737524B2 (en) * | 2002-03-25 | 2004-05-18 | Paul K. Smith | Activated polyethylene glycol compounds |
US20040009944A1 (en) * | 2002-05-10 | 2004-01-15 | Inex Pharmaceuticals Corporation | Methylated immunostimulatory oligonucleotides and methods of using the same |
EP3100719A3 (en) | 2002-05-15 | 2017-02-22 | California Pacific Medical Center | Delivery of nucleic acid-like compounds |
JP4814520B2 (ja) * | 2002-05-15 | 2011-11-16 | エンドサイト,インコーポレイテッド | ビタミン−マイトマイシン結合体 |
CN100386068C (zh) * | 2002-12-03 | 2008-05-07 | 布朗歇特洛克菲勒神经科学研究所 | 传输物质穿过血脑屏障的人工低密度脂蛋白载体 |
NZ541846A (en) | 2003-01-27 | 2008-12-24 | Endocyte Inc | Vitamin receptor binding drug delivery conjugates |
EP1675614A2 (en) * | 2003-10-11 | 2006-07-05 | Inex Pharmaceuticals Corp. | Methods and compositions for enhancing innate immunity and antibody dependent cellular cytotoxicity |
US20050191344A1 (en) * | 2004-01-15 | 2005-09-01 | Samuel Zalipsky | Liposome composition for delivery of therapeutic agents |
US7282590B2 (en) * | 2004-02-12 | 2007-10-16 | The Research Foundation Of State University Of New York | Drug conjugates |
US7931693B2 (en) * | 2004-02-26 | 2011-04-26 | Endosphere, Inc. | Method and apparatus for reducing obesity |
EP1734991A4 (en) * | 2004-04-14 | 2012-10-24 | Avirid Inc | COMPOSITIONS COMPRISING MODIFIED NUCLEASES DIRECTED AGAINST VIRAL NUCLEIC ACIDS AND METHODS OF USE FOR THE PREVENTION AND TREATMENT OF VIRAL DISEASES |
JP2007533750A (ja) * | 2004-04-21 | 2007-11-22 | アルザ コーポレイション | 緩和なチオール分解条件下で遊離可能なポリマー結合体 |
KR20070010175A (ko) * | 2004-04-21 | 2007-01-22 | 알자 코포레이션 | 온화한 가티올분해 조건하에서 방출될 수 있는 폴리머콘쥬게이트 |
US8288557B2 (en) * | 2004-07-23 | 2012-10-16 | Endocyte, Inc. | Bivalent linkers and conjugates thereof |
WO2006029150A2 (en) * | 2004-09-03 | 2006-03-16 | Alza Corporation | Endogenously-formed conjugate of albumin |
TW200612993A (en) * | 2004-10-08 | 2006-05-01 | Alza Corp | Lipopolymer conjugates |
CA2584583A1 (en) * | 2004-10-28 | 2006-05-11 | Alza Corporation | Lyophilized liposome formulations and method |
US8044200B2 (en) * | 2005-03-16 | 2011-10-25 | Endocyte, Inc. | Synthesis and purification of pteroic acid and conjugates thereof |
WO2007022493A2 (en) * | 2005-08-19 | 2007-02-22 | Endocyte, Inc. | Ligand conjugates of vinca alkaloids, analogs, and derivatives |
CN103893778A (zh) * | 2005-08-19 | 2014-07-02 | 恩多塞特公司 | 多药物配体缀合物 |
CA2657769C (en) * | 2006-07-19 | 2014-11-18 | The Board Of Regents Of The University Of Texas System | Preparations of phospholipids and pharmaceuticals containing 5-amino salicylic acid for the treatment of inflammatory bowel disease |
WO2008091655A2 (en) * | 2007-01-23 | 2008-07-31 | The Regents Of The University Of California | Methods, compositions and device for directed and controlled heating and release of agents |
WO2008101231A2 (en) | 2007-02-16 | 2008-08-21 | Endocyte, Inc. | Methods and compositions for treating and diagnosing kidney disease |
EP2489372A3 (en) | 2007-03-14 | 2013-01-02 | Endocyte, Inc. | Binding ligand linked drug delivery conjugates of tubulysins |
ITRM20070327A1 (it) * | 2007-06-11 | 2008-12-12 | Univ Palermo | Vettori colloidali a struttura poliamminoacidica per il rilascio orale di peptidi e proteine e relativo metodo di produzione. |
CN104383553A (zh) * | 2007-06-25 | 2015-03-04 | 恩多塞特公司 | 含有亲水性间隔区接头的共轭物 |
US9877965B2 (en) | 2007-06-25 | 2018-01-30 | Endocyte, Inc. | Vitamin receptor drug delivery conjugates for treating inflammation |
US20100210575A1 (en) * | 2007-06-29 | 2010-08-19 | Wisconsin Alumni Research Foundation | Structuring effect of cholesterol in peg-phospholipid micelles, drug delivery of amphotericin b, and combination antifungals |
WO2009013115A2 (en) * | 2007-07-20 | 2009-01-29 | Basf Se | Vesicles comprising a transmembrane transport trigger system |
MX2010004400A (es) | 2007-10-23 | 2010-05-20 | Nektar Therapeutics | Polimeros de multiples brazos dirigidos a la hidroxiapatita y conjugados de estos. |
WO2009055562A1 (en) | 2007-10-25 | 2009-04-30 | Endocyte, Inc. | Tubulysins and processes for preparing |
US9259398B1 (en) * | 2007-11-26 | 2016-02-16 | Abbott Cardiovascular Systems Inc. | Bioactive agent-loaded targeting micelles |
EP3415151A1 (en) * | 2008-05-23 | 2018-12-19 | The University of British Columbia | Modified drugs for use in liposomal nanoparticles |
CN102388073B (zh) * | 2009-02-04 | 2015-11-25 | 布里格姆及妇女医院股份有限公司 | 纳米级铂化合物及其使用方法 |
JP6297776B2 (ja) | 2009-05-27 | 2018-03-20 | セレクタ バイオサイエンシーズ インコーポレーテッドSelecta Biosciences,Inc. | 免疫調節薬−高分子化合物 |
JP5933437B2 (ja) * | 2009-08-26 | 2016-06-08 | セレクタ バイオサイエンシーズ インコーポレーテッドSelecta Biosciences,Inc. | T細胞ヘルプを誘発する組成物 |
WO2011051916A2 (en) * | 2009-11-02 | 2011-05-05 | Universite De Geneve | Stabilized protein formulations and use thereof |
US20110244026A1 (en) | 2009-12-01 | 2011-10-06 | Braydon Charles Guild | Delivery of mrna for the augmentation of proteins and enzymes in human genetic diseases |
WO2011119995A2 (en) | 2010-03-26 | 2011-09-29 | Cerulean Pharma Inc. | Formulations and methods of use |
DE102010042338A1 (de) * | 2010-10-12 | 2012-04-12 | Bayer Technology Services Gmbh | Zusammensetzung zur Behandlung von Krebs mit kontrollierter Freisetzung des Wirkstoffes |
EA201390660A1 (ru) | 2010-11-05 | 2013-11-29 | Селекта Байосайенсиз, Инк. | Модифицированные никотиновые соединения и связанные способы |
KR102283951B1 (ko) | 2011-04-29 | 2021-08-02 | 셀렉타 바이오사이언시즈, 인크. | 항원-특이적 이펙터 t 세포의 결실을 위한 관용원성 합성 나노운반체 |
EP4212514A1 (en) | 2011-06-08 | 2023-07-19 | Translate Bio, Inc. | Cleavable lipids |
BR112013031553A2 (pt) | 2011-06-08 | 2020-11-10 | Shire Human Genetic Therapies, Inc. | composições, mrna que codifica para uma hgla e seu uso, uso de pelo menos uma molécula de mrna e um veículo de transferência e uso de um mrna que codifica para proteína exógena |
EP2606884A1 (en) | 2011-12-21 | 2013-06-26 | Ecole Polytechnique Fédérale de Lausanne (EPFL) | Inhibitors of notch signaling pathway and use thereof in treatment of cancers |
WO2013126797A1 (en) | 2012-02-24 | 2013-08-29 | Purdue Research Foundation | Cholecystokinin b receptor targeting for imaging and therapy |
US20140080175A1 (en) | 2012-03-29 | 2014-03-20 | Endocyte, Inc. | Processes for preparing tubulysin derivatives and conjugates thereof |
CN104487055A (zh) | 2012-03-29 | 2015-04-01 | 夏尔人类遗传性治疗公司 | 脂质衍生的中性纳米颗粒 |
US20150267192A1 (en) | 2012-06-08 | 2015-09-24 | Shire Human Genetic Therapies, Inc. | Nuclease resistant polynucleotides and uses thereof |
JP2015536323A (ja) | 2012-10-16 | 2015-12-21 | エンドサイト・インコーポレイテッドEndocyte, Inc. | 非天然アミノ酸を含む薬物送達結合体および使用方法 |
EA201591229A1 (ru) | 2013-03-14 | 2016-01-29 | Шир Хьюман Дженетик Терапис, Инк. | Способы очистки матричной рнк |
UA117008C2 (uk) | 2013-03-14 | 2018-06-11 | Шир Хьюман Дженетік Терапіс, Інк. | IN VITRO ТРАНСКРИБОВАНА мРНК ТА КОМПОЗИЦІЯ, ЩО ЇЇ МІСТИТЬ, ДЛЯ ЗАСТОСУВАННЯ В ЛІКУВАННІ МУКОВІСЦИДОЗУ В ССАВЦЯ |
US9827552B2 (en) | 2013-07-17 | 2017-11-28 | Clemson University | Functionalized lipid modification of solid phase surfaces for use in chromatography |
EA201690576A1 (ru) | 2013-10-22 | 2016-10-31 | Шир Хьюман Дженетик Терапис, Инк. | Липидные композиции для доставки матричной рнк |
EP3501605B1 (en) | 2013-10-22 | 2023-06-28 | Translate Bio, Inc. | Mrna therapy for argininosuccinate synthetase deficiency |
CA2928186A1 (en) | 2013-10-22 | 2015-04-30 | Shire Human Genetic Therapies, Inc. | Mrna therapy for phenylketonuria |
KR102470198B1 (ko) | 2014-04-25 | 2022-11-22 | 샤이어 휴먼 지네틱 테라피즈 인크. | 메신저 rna 의 정제 방법 |
MA48050A (fr) | 2014-05-30 | 2020-02-12 | Translate Bio Inc | Lipides biodégradables pour l'administration d'acides nucléiques |
WO2015191576A1 (en) | 2014-06-09 | 2015-12-17 | Lipomedix Pharmaceuticals Ltd. | Combination therapy comprising a liposomal prodrug of mitomycin c and radiotherapy |
EP3160959B1 (en) | 2014-06-24 | 2023-08-30 | Translate Bio, Inc. | Stereochemically enriched compositions for delivery of nucleic acids |
JP6859275B2 (ja) | 2015-03-17 | 2021-04-14 | リポメディックス・ファーマシューティカルズ・リミテッドLipomedix Pharmaceuticals Ltd. | 膀胱がんの治療方法 |
CN106519211B (zh) * | 2015-09-10 | 2018-10-09 | 中国科学院高能物理研究所 | 一种两亲性聚合物以及由其形成的磁性胶束纳米载体和其用途 |
CN106519221B (zh) * | 2015-09-10 | 2019-04-26 | 中国科学院高能物理研究所 | 一种聚乙二醇/聚酰胺胺共聚物、其制备方法及包含该共聚物的两亲性siRNA载体 |
CN105866311B (zh) * | 2016-05-25 | 2017-05-31 | 福建出入境检验检疫局检验检疫技术中心 | 测定鸡肉中抗病毒药物残留的uplc‑ms/ms方法 |
GB2552301A (en) * | 2016-07-11 | 2018-01-24 | Evox Therapeutics Ltd | Metabolic drug loading of EVs |
WO2018089481A1 (en) | 2016-11-08 | 2018-05-17 | Mallinckrodt Llc | Mitomycin c prodrug liposome formulations and uses thereof |
WO2018157154A2 (en) | 2017-02-27 | 2018-08-30 | Translate Bio, Inc. | Novel codon-optimized cftr mrna |
WO2018213476A1 (en) | 2017-05-16 | 2018-11-22 | Translate Bio, Inc. | Treatment of cystic fibrosis by delivery of codon-optimized mrna encoding cftr |
WO2019016208A1 (en) * | 2017-07-17 | 2019-01-24 | Technische Universiteit Eindhoven | APPLICABLE CHEMICAL COMPOSITION COMPRISING AN AGENT CONJUGATED TO A HYDROPHOBIC PART AND A SUPPORT |
WO2019040491A1 (en) | 2017-08-22 | 2019-02-28 | Dynavax Technologies Corporation | MODIFIED ALKYL CHAIN IMIDAZOQUINOLINE TLR7 / 8 AGONIST COMPOUNDS AND USES THEREOF |
US10722591B2 (en) | 2017-11-14 | 2020-07-28 | Dynavax Technologies Corporation | Cleavable conjugates of TLR7/8 agonist compounds, methods for preparation, and uses thereof |
US11472771B2 (en) | 2018-06-21 | 2022-10-18 | Cellestia Biotech Ag | Process for making amino diaryl ethers and amino diaryl ethers hydrochloride salts |
CA3108544A1 (en) | 2018-08-24 | 2020-02-27 | Translate Bio, Inc. | Methods for purification of messenger rna |
JP2022517352A (ja) * | 2019-01-11 | 2022-03-08 | リポメディックス・ファーマシューティカルズ・リミテッド | マイトマイシンcのリポソーム化プロドラッグを含むリポソーム組成物および製造法 |
US20220169642A1 (en) | 2019-04-10 | 2022-06-02 | Cellestia Biotech Ag | Compounds for the treatment of oncovirus induced cancer and methods of use thereof |
EP4008324A1 (en) | 2020-12-07 | 2022-06-08 | Cellestia Biotech AG | Combinations comprising an inhibitor of an anti-apoptotic protein, such as bcl-2, bcl-xl, bclw or mcl-1, and a notch signaling pathway inhibitor for treating cancer |
US20240041884A1 (en) | 2020-12-07 | 2024-02-08 | Cellestia Biotech Ag | Pharmaceutical Combinations for Treating Cancer |
WO2022253794A2 (en) | 2021-06-02 | 2022-12-08 | Cellestia Biotech Ag | Method for treating an autoimmune and inflammatory disease |
WO2023079132A1 (en) | 2021-11-08 | 2023-05-11 | Cellestia Biotech Ag | Pharmaceutical combinations for treating cancer |
EP4223292A1 (en) | 2022-02-07 | 2023-08-09 | Cellestia Biotech AG | Pharmaceutical combinations for treating cancer |
Family Cites Families (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
JPS5240B2 (da) * | 1973-12-17 | 1977-01-05 | ||
GB8430252D0 (en) | 1984-11-30 | 1985-01-09 | Beecham Group Plc | Compounds |
US4766106A (en) | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
US4917888A (en) | 1985-06-26 | 1990-04-17 | Cetus Corporation | Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation |
US5059421A (en) | 1985-07-26 | 1991-10-22 | The Liposome Company, Inc. | Preparation of targeted liposome systems of a defined size distribution |
JPH0615532B2 (ja) * | 1986-02-03 | 1994-03-02 | テルモ株式会社 | 5−フルオロウラシル誘導体およびこれを含有する医薬製剤 |
US4766105A (en) * | 1986-10-31 | 1988-08-23 | Shell Oil Company | Ethylene oxide catalyst and process for preparing the catalyst |
JPH01113391A (ja) * | 1987-10-24 | 1989-05-02 | Kyowa Hakko Kogyo Co Ltd | マイトマイシン誘導体 |
US4952394A (en) * | 1987-11-23 | 1990-08-28 | Bristol-Myers Company | Drug-monoclonal antibody conjugates |
ZA886812B (en) * | 1987-11-23 | 1989-07-26 | Bristol Myers Co | Anti-tumor prodrugs |
US5103556A (en) | 1988-05-05 | 1992-04-14 | Circon Corporation | Method of manufacturing an electrohydraulic probe |
US4902502A (en) | 1989-01-23 | 1990-02-20 | Cetus Corporation | Preparation of a polymer/interleukin-2 conjugate |
US5585112A (en) | 1989-12-22 | 1996-12-17 | Imarx Pharmaceutical Corp. | Method of preparing gas and gaseous precursor-filled microspheres |
TW211015B (da) * | 1990-01-11 | 1993-08-11 | Nippon Shinyaku Co Ltd | |
US5169934A (en) | 1990-05-14 | 1992-12-08 | Anergen, Inc. | Intracellularly cleavable compounds |
DE69329073T2 (de) | 1992-03-23 | 2001-01-18 | Georgetown University, Washington | In liposomen verkapseltes taxol und verwendungsverfahren |
JP2813511B2 (ja) * | 1992-06-10 | 1998-10-22 | 大日本スクリーン製造株式会社 | ロールコータによる基板表面への塗液塗布方法 |
WO1994005259A1 (en) | 1992-09-02 | 1994-03-17 | Georgetown University | Method of encapsulating anthracycline glycosides in liposomes |
US5395619A (en) | 1993-03-03 | 1995-03-07 | Liposome Technology, Inc. | Lipid-polymer conjugates and liposomes |
US5820873A (en) * | 1994-09-30 | 1998-10-13 | The University Of British Columbia | Polyethylene glycol modified ceramide lipids and liposome uses thereof |
NZ298712A (en) * | 1995-01-16 | 1998-12-23 | Commw Scient Ind Res Org | Fatty acid acyl group conjugates as therapeutic compounds |
WO1996022302A1 (en) | 1995-01-20 | 1996-07-25 | Florida State University | Sex-specific dna probe for parrots, methods and kits |
JPH09268190A (ja) * | 1996-04-02 | 1997-10-14 | Sagami Chem Res Center | マイトマイシンc誘導体及び非受容体型チロシンキナーゼ阻害剤 |
TW520297B (en) | 1996-10-11 | 2003-02-11 | Sequus Pharm Inc | Fusogenic liposome composition and method |
AU4907897A (en) | 1996-10-11 | 1998-05-11 | Sequus Pharmaceuticals, Inc. | Therapeutic liposome composition and method |
JPH1160499A (ja) | 1997-08-22 | 1999-03-02 | Hiroshi Maeda | 抗腫瘍剤 |
SE513149C2 (sv) | 1997-12-05 | 2000-07-17 | Katarina Edwards | Läkemedelsdistributionssystem med tvåstegsmålsökning, till specifika celler eller vävnad och till dess cellkärna |
US6180095B1 (en) * | 1997-12-17 | 2001-01-30 | Enzon, Inc. | Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents |
PL193352B1 (pl) * | 1998-04-28 | 2007-02-28 | Applied Research Systems | Koniugat poliol-interferon ß, sposób jego wytwarzania i jego zastosowanie oraz kompozycja farmaceutyczna |
US7238368B2 (en) | 1999-04-23 | 2007-07-03 | Alza Corporation | Releasable linkage and compositions containing same |
US7112337B2 (en) | 1999-04-23 | 2006-09-26 | Alza Corporation | Liposome composition for delivery of nucleic acid |
US7303760B2 (en) | 1999-04-23 | 2007-12-04 | Alza Corporation | Method for treating multi-drug resistant tumors |
KR100669053B1 (ko) * | 1999-04-23 | 2007-01-15 | 알자 코포레이션 | 리포좀에 사용하기 위한 절단가능 결합을 갖는 콘쥬게이트 |
WO2000064483A2 (en) | 1999-04-23 | 2000-11-02 | Alza Corporation | Releasable linkage and compositions containing same |
WO2001026625A2 (en) | 1999-10-08 | 2001-04-19 | Alza Corp | Neutral-cationic lipid for nucleic acid and drug delivery |
EP2295450B1 (en) | 2000-09-29 | 2015-01-28 | Merck Sharp & Dohme Corp. | Pegylated interleukin-10 |
US7260330B2 (en) * | 2002-11-04 | 2007-08-21 | The Boeing Company | Optical communication system using correlation receiver |
-
2000
- 2000-04-21 KR KR1020017013571A patent/KR100669053B1/ko not_active IP Right Cessation
- 2000-04-21 EP EP05008357A patent/EP1579874A3/en not_active Withdrawn
- 2000-04-21 CN CNB008079013A patent/CN100512879C/zh not_active Expired - Lifetime
- 2000-04-21 IL IL14605500A patent/IL146055A0/xx active IP Right Grant
- 2000-04-21 EP EP07018132A patent/EP1880736A1/en not_active Withdrawn
- 2000-04-21 JP JP2000613474A patent/JP4558952B2/ja not_active Expired - Fee Related
- 2000-04-21 EP EP00928321A patent/EP1173222B1/en not_active Expired - Lifetime
- 2000-04-21 ES ES00928321T patent/ES2272280T3/es not_active Expired - Lifetime
- 2000-04-21 US US09/556,610 patent/US6365179B1/en not_active Expired - Lifetime
- 2000-04-21 KR KR1020017013588A patent/KR100642955B1/ko not_active IP Right Cessation
- 2000-04-21 DE DE60030965T patent/DE60030965T2/de not_active Expired - Lifetime
- 2000-04-21 MX MXPA01010750A patent/MXPA01010750A/es active IP Right Grant
- 2000-04-21 AU AU46577/00A patent/AU769425B2/en not_active Ceased
- 2000-04-21 AT AT00928321T patent/ATE340592T1/de not_active IP Right Cessation
- 2000-04-21 MX MXPA01010751A patent/MXPA01010751A/es not_active Application Discontinuation
- 2000-04-21 HU HU0200797A patent/HUP0200797A3/hu unknown
- 2000-04-21 DK DK00928321T patent/DK1173222T3/da active
- 2000-04-21 WO PCT/US2000/010922 patent/WO2000064484A2/en active IP Right Grant
- 2000-04-21 HU HU0201425A patent/HUP0201425A3/hu unknown
- 2000-04-21 CN CNB00807707XA patent/CN1244376C/zh not_active Expired - Fee Related
- 2000-04-21 US US09/556,056 patent/US6342244B1/en not_active Expired - Lifetime
- 2000-04-21 CA CA2369595A patent/CA2369595C/en not_active Expired - Lifetime
-
2001
- 2001-10-15 US US09/982,336 patent/US6605299B2/en not_active Expired - Lifetime
- 2001-10-18 IL IL146055A patent/IL146055A/en not_active IP Right Cessation
- 2001-10-22 NO NO20015144A patent/NO20015144L/no not_active Application Discontinuation
- 2001-10-23 ZA ZA200108724A patent/ZA200108724B/en unknown
- 2001-10-23 ZA ZA200108726A patent/ZA200108726B/en unknown
-
2002
- 2002-01-25 US US10/057,839 patent/US6984396B2/en not_active Expired - Lifetime
- 2002-05-13 HK HK02103601.3A patent/HK1041820B/zh not_active IP Right Cessation
-
2003
- 2003-02-21 US US10/371,169 patent/US6849270B2/en not_active Expired - Lifetime
-
2005
- 2005-01-14 US US11/035,707 patent/US7285622B2/en not_active Expired - Lifetime
- 2005-08-12 US US11/202,913 patent/US7276248B2/en not_active Expired - Lifetime
-
2007
- 2007-09-19 US US11/903,199 patent/US7608687B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1173222T3 (da) | Konjugat med en spaltelig binding til brug i et liposom | |
DE50014571D1 (de) | Träger-pharmaka-konjugate | |
WO2005034909A3 (en) | Hyperbranched polymer conjugates via non-enzymatic cleavable linker | |
AU5076799A (en) | Trifunctional reagent for conjugation to a biomolecule | |
AU2002341034B2 (en) | Metal substituted non centrosimmetrical phthalocyanine analogues, their preparation and use in photodynamic therapy and in vivo diagnostic | |
ATE335719T1 (de) | Polyamine und ihre therapeutische verwendung | |
TR200200912T2 (tr) | APRIL (çoğalma uyarıcı ligand) reseptörü (BCMA) ve kullanımları | |
CA2249320A1 (en) | Glycosylated humanized b-cell specific antibodies | |
CA2158054A1 (en) | Conjugates of proteins and bifunctional ligands | |
ES2077098T3 (es) | Proteinas modificadas con sacaridos, solubles en agua. | |
DK1327146T3 (da) | Forbindelse med et forgrenet linkermolekyle | |
WO2000064483A3 (en) | Releasable linkage and compositions containing same | |
EP0579802A4 (en) | Bicycle-polyazamacrocyclocarboxylic acid complexes, conjugates, preparation and use as contrast agents | |
DE602005015855D1 (de) | Verfahren zur herstellung von immunogenen konjugaten | |
TR199902775T2 (xx) | 20(S)-Kamptotesin glikokonjugeleri. | |
ATE160943T1 (de) | Bicycloazamakrocyclophosphon-säure, komplexe, konjugate, kontrastmittel und herstellung | |
CA2381123A1 (en) | Actinium-225 complexes and conjugates for radioimmunotherapy | |
TR200100651T2 (tr) | İki işlevli antikorlar ve bunların tümör-önleyici amilleri hedeflemede kullanımı | |
RU98106367A (ru) | Способ приготовления эритроцитарного антигенного диагностикума | |
DK5288D0 (da) | Vandoploeseligt polymerkonjugat, dets fremstilling og anvendelse | |
伊藤正照 | Preparation of photoresponsive self-assembled monolayer using carboranes | |
BR9900258A (pt) | Processo de mistura de borracha aglutinada | |
BR8000770U (pt) | Conjunto descartável para higiene diária de gatosdomésticos | |
JPH0298954U (da) | ||
JPS62125107U (da) |